Ropes & Gray Advises Amarin in License and Distribution Agreement with CSL Seqirus to Commercialize Cardiovascular Drug in Australia and New Zealand
Ropes & Gray represented pharmaceutical company Amarin Corporation plc in an agreement with CSL Seqirus for an exclusive license and distribution agreement under which Amarin will license exclusive rights to cardiovascular medicine VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand. The transaction was announced on February 28.
Under the agreement, CSL Seqirus will in-license VAZKEPA from Amarin and will be responsible for market access and reimbursement efforts, distribution and commercial promotion for VAZKEPA across Australia and New Zealand. Amarin will receive an upfront payment and be eligible for event-related and product-related milestone payments. Amarin will be responsible for supplying finished product to CSL Seqirus.
The Ropes & Gray team included life sciences licensing partner Abigail Gregor and associate Rob Treut.